Osteopenia | Jotup

Why you shouldn’t be afraid to start running after middle age

Retrieved on:

星期五, 四月 19, 2024

As someone who started marathon running in mid-life, I know how many aches and pains (and doubts) you can have if you take on the challenge to start running at an older age.

Key Points:

As someone who started marathon running in mid-life, I know how many aches and pains (and doubts) you can have if you take on the challenge to start running at an older age.
Hobbling around my orthopaedic hospital after my first marathon actually led me to do research on runners.
The high-resolution MRI scans found most of the 115 middle-aged participants had abnormalities in their knees before starting marathon training.
But while osteoarthritis is more common after middle age, it may actually be a lack of activity that leads to osteoarthritis.

Reduced muscle use, whether it is through inactivity or sarcopenia or both, also reduces the production of anti-inflammatory myokines from the muscles.
These chemicals are released when we exercise, and help reduce joint swelling and calm irritated joint linings.
This effect is pronounced in runners because running uses some of the largest muscles in the body – such as the glutes, quadriceps and hamstrings.

Where to begin

If you want to start running, the main message is to ease into it to reduce the risk of injury.
One of the best ways to ease into running in mid-life is the NHS Couch to 5K running programme.
It’s a free guide that will help you gradually work up towards running 5km in just nine weeks.
If you’ve experienced any of these problems, you’ll want to be careful when exercising to avoid further damage.

Alister Hart receives funding from 3 charities: The Rosetrees Trust, Arthroplasty for Arthritis and The Maurice Hatter Foundation.

Studies Explore: Semaglutide Use and Its Impact on Total Hip Arthroplasty Postoperative Outcomes

Retrieved on:

星期一, 二月 12, 2024

SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Ozempic and Wegovy, which both contain the active ingredient semaglutide, have received recent attention in the media and on social platforms for its effectiveness in supporting weight loss. Ozempic, which is approved for people with Type 2 diabetes, has now become a widely accepted choice for weight loss, and Wegovy was approved in 2021 for long-term weight management.

Key Points:

As the use of semaglutide increases among patients for diabetes and/or weight management, it's important to understand how it can impact postoperative outcomes of joint replacement surgery.
Two studies presented at the AAOS 2024 Annual Meeting looked at the use of semaglutide and its impact on outcomes of total hip arthroplasty (THA), finding that patients who take semaglutide at the time of THA experience similar postoperative outcomes to those who do not take the drug.
The researchers found that postoperative complications after THA are similar between obese patients using semaglutide compared to those who did not.
Both cohorts experienced a similar risk of hip arthroplasty revision, prosthesis infection, opioid-related disorders, surgical site infections, mortality, respiratory failure, pulmonary embolism, deep vein thrombosis, postoperative dehydration, cardiovascular comorbidities, shock, and prosthesis dislocations.

Sparrow Pharmaceuticals Doses First Patient in Phase 2 ACSpire Study of SPI-62 for Autonomous Cortisol Secretion

Retrieved on:

星期二, 十月 24, 2023

This trial will complement the ongoing Phase 2 RESCUE study (NCT number: NCT05307328 ) for the treatment of ACTH-dependent Cushing’s syndrome.

Key Points:

This trial will complement the ongoing Phase 2 RESCUE study (NCT number: NCT05307328 ) for the treatment of ACTH-dependent Cushing’s syndrome.
The study will examine SPI-62's effect on morbidities of hypercortisolism including diabetes or impaired glucose tolerance, hyperlipidemia, hypertension, and osteopenia.
Sparrow is actively enrolling up to 30 participants in ACSpire at sites in the United States, soon to be joined by sites in Romania, France, and the United Kingdom.
To learn more about Sparrow Pharmaceuticals and its clinical trials, visit the website at www.sparrowpharma.com .

Digital X-ray Systems Markets - Global Forecast to 2030: Market Set to Reach $13.29 Billion by 2030, Driven by Rising Geriatric Population and Chronic Diseases

Retrieved on:

星期五, 十月 20, 2023

The global digital X-ray systems market is projected to reach $13.29 billion by 2030, at a CAGR of 7.8% from 2023 to 2030.

Key Points:

The global digital X-ray systems market is projected to reach $13.29 billion by 2030, at a CAGR of 7.8% from 2023 to 2030.
The growth of this market is driven by the rising geriatric population, coupled with the growing burden of chronic diseases, the increasing adoption of teleradiology, and technological advancements leading to a higher preference for digital X-ray systems.
Furthermore, emerging economies and the increasing integration of Artificial Intelligence (AI) into digital X-ray systems are expected to offer significant market growth opportunities.
In 2023, the fixed digital X-ray systems segment is expected to account for the largest share of the digital X-ray systems market.

Amolyt Pharma Announces Data on Prevalence of Bone Disease in Patients with Hypoparathyroidism and Favorable Bone Effects of Eneboparatide at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

Retrieved on:

星期一, 十月 16, 2023

LYON, France, and CAMBRDIGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced data from two posters that were presented at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023, in Vancouver, BC, Canada. The data include a prospective analysis of bone disease in patients with hypoparathyroidism from the Canadian National Hypoparathyroidism Registry with evidence of significant bone disease burden in postmenopausal females (PMF). In addition, data from both pre-clinical and clinical studies of eneboparatide continue to demonstrate its ability to restore balanced bone turnover, preserving bone integrity, while maintaining calcium homeostasis and normalizing urinary calcium.

Key Points:

The data include a prospective analysis of bone disease in patients with hypoparathyroidism from the Canadian National Hypoparathyroidism Registry with evidence of significant bone disease burden in postmenopausal females (PMF).
In addition, data from both pre-clinical and clinical studies of eneboparatide continue to demonstrate its ability to restore balanced bone turnover, preserving bone integrity, while maintaining calcium homeostasis and normalizing urinary calcium.
“We’re very pleased to have a strong presence at this year’s ASBMR Annual Meeting.
These data increase our understanding of the relationship between hypoparathyroidism and bone strength.

Bone Health Technologies to Present Clinical Data from Pivotal Trial of Wearable Treatment for Osteopenia in Post-Menopausal Women at Endo 2023

Retrieved on:

星期五, 六月 16, 2023

The double-blinded, sham-controlled study enrolled 126 postmenopausal women with low bone mass who were not on bone-active medications. The data being presented are strong evidence that supports the efficacy of the Osteoboost in reducing the decline of bone strength and bone density. The primary outcome measurement was the change in vertebral strength, as measured by Biomechanical Computed Tomography using finite element analysis. Per Protocol (PP) - subjects (those who used the device a minimum of 3 times per week throughout the year) in the Active Treatment group lost, on average, 0.48% bone strength, while those in the Sham group lost 2.84%, with a relative difference of 2.36% (P=0.014)-- an 82% reduction in the rate of bone strength loss. Additionally, CT measurement of vertebral bone density was conducted and showed a 1.68% relative benefit for those using the Osteoboost– an 85% reduction in loss of bone density (P=0.008) in the PP group. Zero serious adverse events were reported.

Key Points:

CHICAGO, June 16, 2023 (GLOBE NEWSWIRE) -- Bone Health Technologies (BHT), a pioneer in health technologies for preventing and treating bone health diseases, is presenting pivotal trial data for Osteoboost, a novel treatment for low bone mass in postmenopausal women, at Endo 2023.
Bone Health Technologies has filed for Class 2 Prescription De Novo Approval with the FDA and was previously awarded Breakthrough Device Status.
The data being presented are strong evidence that supports the efficacy of the Osteoboost in reducing the decline of bone strength and bone density.
Bone Health Technologies is proud to have contributed to this groundbreaking study and will share findings with attendees at ENDO 2023.

X-Bolt Orthopedics Announces FDA 510(k) Clearance for Pro-X1™ Trochanteric Nail

Retrieved on:

星期二, 三月 7, 2023

Titanium, Femur, Trauma, Osteopenia, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, Food, Fracture, FDA, OTA, Osteoporosis, Medical device

DUBLIN, March 7, 2023 /PRNewswire/ -- X-Bolt, an emerging innovator of orthopedic devices, is pleased to announce that its hip fracture solution, the Pro-X1 Trochanteric Nail, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Key Points:

DUBLIN, March 7, 2023 /PRNewswire/ -- X-Bolt, an emerging innovator of orthopedic devices, is pleased to announce that its hip fracture solution, the Pro-X1 Trochanteric Nail, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
"We are thrilled to receive FDA clearance for the Pro-X1 Trochanteric Nail," said Brian Thornes, X-Bolt's founder and inventor of the globally recognized product, TightRope®.
The Pro-X1 Trochanteric Nail features a titanium nail construct with a reversibly expanding bolt instead of a typical lag screw.
The Pro-X1™ Trochanteric Nailing System is intended for use in fracture fixation in the femur in adults with osteopenia or osteoporosis.

Surgical Robots Market to be Worth $25.47 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®

Retrieved on:

星期一, 二月 27, 2023

With benefits such as greater control, flexibility, and precision, demand for surgical robots is expected to increase at a higher rate.

Key Points:

With benefits such as greater control, flexibility, and precision, demand for surgical robots is expected to increase at a higher rate.
The advantages of robot-assisted surgeries over conventional surgical methods are primarily triggering the use of surgical robots in several complex surgical processes.
Quick Buy – Surgical Robots Market Research Report: https://www.meticulousresearch.com/Checkout/80971454
Based on end user, in 2023, the hospitals segment is expected to account for the largest share of the global surgical robots market.
In 2023, the U.S. is expected to account for the largest share of the surgical robots market in North America.

Surgical Robots Market to be Worth $25.47 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®

Retrieved on:

星期一, 二月 27, 2023

With benefits such as greater control, flexibility, and precision, demand for surgical robots is expected to increase at a higher rate.

Key Points:

With benefits such as greater control, flexibility, and precision, demand for surgical robots is expected to increase at a higher rate.
The advantages of robot-assisted surgeries over conventional surgical methods are primarily triggering the use of surgical robots in several complex surgical processes.
Quick Buy – Surgical Robots Market Research Report: https://www.meticulousresearch.com/Checkout/80971454
Based on end user, in 2023, the hospitals segment is expected to account for the largest share of the global surgical robots market.
In 2023, the U.S. is expected to account for the largest share of the surgical robots market in North America.

Prosthetics and Orthotics Global Market Report 2022: Increasing Prevalence of Osteosarcoma Fuels Sector - ResearchAndMarkets.com

Retrieved on:

星期三, 十二月 28, 2022

The "Prosthetics and Orthotics Market Size, Share & Trend Analysis Report by Type (Orthotics (Upper Limb, Lower Limb, Spinal), Prosthetics (Upper Extremity, Lower Extremity)), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Prosthetics and Orthotics Market Size, Share & Trend Analysis Report by Type (Orthotics (Upper Limb, Lower Limb, Spinal), Prosthetics (Upper Extremity, Lower Extremity)), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
The global prosthetics and orthotics market size is expected to reach USD 9.31 billion by 2030, registering a CAGR of 4.3% during the forecast period.
Increasing incidences of sports injuries, rising occurrence of osteosarcoma, and growing geriatric population base are the key factors driving the market growth.
The rising geriatric population across the globe has become one of the key factors driving demand for prosthetics & orthotics.